Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors

Autor: Hongxia Li, Giovanni Fucà, Brian Mcguinness, Hongwei Du, Elena Dukhovlinova, Xin Zhou, Colette Johnston, Peishun Shou, Guanmeng Wang, Gianpietro Dotti
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Cytotoxicity
Immunologic

Glutamate Carboxypeptidase II
Male
Cancer Research
medicine.medical_treatment
T-Lymphocytes
MSLN
Immunoglobulin Variable Region
Lymphocyte Activation
Immunotherapy
Adoptive

Mice
Inbred NOD

Immunology and Allergy
RC254-282
Receptors
Chimeric Antigen

biology
Chemistry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
CAR-T
medicine.anatomical_structure
Phenotype
Oncology
Mesothelin
Antigens
Surface

Molecular Medicine
Cytokines
immunotherapy
Antibody
T cell
Immunology
Antigen
Cell Line
Tumor

medicine
PSMA
Animals
Humans
Pharmacology
Immune Cell Therapies and Immune Cell Engineering
Humabody
Prostatic Neoplasms
tumor escape
Immunotherapy
Xenograft Model Antitumor Assays
Chimeric antigen receptor
In vitro
Coculture Techniques
Tumor Escape
Cancer research
biology.protein
Single-Chain Antibodies
Zdroj: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
ISSN: 2051-1426
Popis: BackgroundChimeric antigen receptor (CAR) T cells are effective in B-cell malignancies. However, heterogeneous antigen expression and antigen loss remain important limitations of targeted immunotherapy in solid tumors. Therefore, targeting multiple tumor-associated antigens simultaneously is expected to improve the outcome of CAR-T cell therapies. Due to the instability of single-chain variable fragments, it remains challenging to develop the simultaneous targeting of multiple antigens using traditional single-chain fragment variable (scFv)-based CARs.MethodsWe used Humabody VH domains derived from a transgenic mouse to obtain fully human prostate-specific membrane antigen (PSMA) VH and mesothelin (MSLN) VH sequences and redirect T cell with VH based-CAR. The antitumor activity and mode of action of PSMA VH and MSLN VH were evaluated in vitro and in vivo compared with the traditional scFv-based CARs.ResultsHuman VH domain-based CAR targeting PSMA and MSLN are stable and functional both in vitro and in vivo. VH modules in the bispecific format are capable of binding their specific target with similar affinity as their monovalent counterparts. Bispecific CARs generated by joining two human antibody VH domains can prevent tumor escape in tumor with heterogeneous antigen expression.ConclusionsFully human antibody VH domains can be used to generate functional CAR molecules, and redirected T cells elicit antitumoral responses in solid tumors at least as well as conventional scFv-based CARs. In addition, VH domains can be used to generate bispecific CAR-T cells to simultaneously target two different antigens expressed by tumor cells, and therefore, achieve better tumor control in solid tumors.
Databáze: OpenAIRE